Paratek Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Paratek Pharmaceuticals

16/03/2023 13:32

* Paratek Pharmaceuticals Inc  PRTK.OQ  reported a quarterly
adjusted loss of 12 cents​​ per share for the quarter ended in
December. The mean expectation of three analysts for the quarter
was for earnings of 9 cents per share.
    * Revenue rose 137.6% to $75.56 million from a year ago;
analysts
expected $63.46 million. 
    * Paratek Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 12 cents​.
    * The mean earnings estimate of analysts had risen by
about 207.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Paratek Pharmaceuticals Inc shares had risen by 2.1% this
quarter.
    * The company reported a quarterly loss of $7.16 million.
    * Wall Street's median 12-month price target for Paratek
Pharmaceuticals Inc is $20.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 16 at 01:32 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      0.09           -0.12          Missed
 Sep. 30 2022      -0.29          -0.38          Missed
 Jun. 30 2022      -0.34          -0.33          Beat
 Mar. 31 2022      -0.35          -0.35          Met